<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=319805651697215&amp;ev=PageView&amp;noscript=1">

Cryoport’s Portfolio of Temperature-Managed Clinical Programs Expands to 45 Trials

July 27, 2015

Lake Forest, CA, July 27, 2015 - Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport” or the “Company”), the leading provider of advanced cryogenic logistics solutions for the life sciences industry, with markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers, animal health, and reproductive medicine, is now supporting approximately 45 clinical trials. The majority of these trials are regenerative therapies including an array of CAR T-cell therapies. In total, these immunotherapy trials are expected to contribute as much as $150 million of revenue for Cryoport over the next five years.

Read More


Tags: deep frozen shipping, clincal trials